This announcement is based on a press release statement from Silo Pharma. With a current ratio of 7.9, the company maintains strong liquidity to fund its development pipeline, though analysts tracked ...

a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in ...